We have previously established a computational pipeline for drug repurposing and identified JNK-IN-5A could modulate the expression of PKLR for effective treatment of non-alcoholic fatty liver disease (Zhang et al. 2022). Here, PKLR is linked to metabolic dysfunction-associated steatotic liver disease.